Mining and Gold Stocks News; LOMIKO (TSX-V: LMR; OTC: LMRMF) ESTABLISHES EXPLORATION CAMP AT VINES LAKE GOLD PROJECT

Vancouver - June 6, 2011 (Investorideas.com mining stocks newswire) – LOMIKO METALS INC. (TSX-V:LMR, OTC: LMRMF, Europe: ISIN: CA54163Q1028, WKN: A0Q9W7,) ("Lomiko" or "the Company) Exploration Manager Lesley Hunt has reports that Lomiko has established an exploration camp to coordinate activities related to the summer exploration program at Vines Lake. Lomiko holds the rights to three contiguous mineral tenures, totaling 1,169 Ha (2,888 Acres) located in the southwestern corner of the Cassiar Gold District or ‘Cassiar Gold Camp'. Exploration activities are to commence in June, 2011 and continue until September, 2011.

This program is designed to target both potentially high-grade gold vein systems, as seen at the adjacent Table Mountain Mine, in addition to the prospect of intrusion related mineralization. Phase I of the program is targeted to begin as soon as weather and snow conditions permit. Phase II will explore follow-up targets resulting from the geological mapping, geochemical and ground geophysical surveys resulting from Phase I.
Due to the property's close proximity to formerly producing mines with a proven history in the Cassiar Mining Camp, it is the opinion of the company that potential exists on the 100% owned Vines Lake Property for discovering new high-grade gold vein systems. Also, there is a potential for other intrusion related mineralization in proximity to the Cassiar Batholith and its associated boundary contacts, over which Lomiko's Vines Lake property claims are located.
Cassiar Area Highlights:

• A new company with Chinese investors known as China Minerals Mining Corporation is located adjacent to the property.
• A fully permitted 270 tonne per day, gravity and flotation mill, power plant, assay laboratory and tailings impoundment facility is owned by China Minerals.
• Approximately 316,000 ounces of gold have been produced at the adjacent Table Mountain Mine from 1979-2007 under various companies.
• Current Resource Estimates for the Table Mountain Mine are 21,471 tonnes grading 18.02 g/t indicated and 65,757 tonnes grading 24.3 g/t inferred were reported at the adjacent property in the May, 2010 NI43-101 Technical Report on the Table Mountain Property by C. Pearson and F.J. Bakker.

Vines Lake Highlights:

• Two significant anomalies have been identified by geophysical surveys.The claims cover formations of the Sylvester group, which are known to contain productive zones of gold mineralization in the area.
• The Vines Lake Property is located approximately two kilometres southwest of the former Erickson gold mine.
• Highway 37 N bisects the property north to south providing excellent access.

Mr. Garth Kirkham, P.Geo is a Director of Lomiko Metals Inc. in addition to being the Qualified Person for the Vines Lake Project and has reviewed the technical data in this news release.
For more information, please contact Paul Gill at 604­729­5312 Email: lomiko@dccnet.com. Website: www.lomiko.com.
On behalf of Lomiko Metals Inc,
Signed: "A. Paul Gill"
A. Paul Gill, President & CEO
We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer/ Disclosure: The following news is paid for and /or published as information only for our readers. Lomiko Metals Inc. (TSX-V: LMR) three month showcase gold stock on Investorideas.com and all related mining portals and blogs (one thousand per month)
Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of principal .This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Biotech and Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Announces Lifting of Clinical Hold on GVAX Prostate Cancer Vaccine

CHICAGO - June 6, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that the FDA's clinical hold on the GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been lifted by FDA. Manufacturing of new GVAX Prostate is complete, and planning for a Phase II clinical trial at the Johns Hopkins Kimmel Cancer Center is underway.

BioSante funded the manufacturing of GVAX Prostate, and the trial will be supported in part by the Prostate Cancer Foundation. Important start-up funding for this study was provided by the OneInSix Foundation.
"The Prostate Cancer Foundation funded the early work at Johns Hopkins University that resulted in the development of the GVAX Prostate Cancer Vaccine. We are pleased to continue support of Dr. Charles Drake and his innovative clinical and laboratory investigations of GVAX at Hopkins," said Howard R. Soule, PhD, executive vice president and chief science officer of the Prostate Cancer Foundation. "We are delighted that the OneInSix Foundation has joined in support of this important prostate cancer program. Under BioSante leadership we are hopeful that GVAX Prostate will be established as a new treatment for men with advanced prostate cancer."
"We are pleased to be working with Johns Hopkins as well as the Foundations on such an important project," said Stephen M. Simes, BioSante's president and chief executive officer. "A joint effort among the various parties involved has resulted in the FDA lifting the GVAX Prostate clinical hold which is a positive step for development of a new prostate cancer vaccine and the men who may benefit. Now that the FDA has approved the first-ever therapeutic cancer vaccine, Provenge, for the treatment of prostate cancer, we have renewed confidence that GVAX Prostate can be a valuable addition to prostate cancer patient care."
Unlike the recently approved Provenge for the treatment of prostate cancer, which requires isolation of cells from the patient that are then modified to produce the vaccine which is then re-introduced into the patient, GVAX Prostate is an off-the-shelf, non-patient-specific vaccine. It is comprised of prostate cancer cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety. GVAX Prostate will be administered via intradermal injections on an outpatient basis. To date, over 1,000 patients have been treated in clinical trials with BioSante cancer vaccines for various types of cancer. Although Phase III trials in prostate cancer were discontinued in 2008, development of GVAX Prostate has been reinitiated in view of the great need among men with prostate cancer and the lessons learned using the vaccine in previous clinical trials.
In addition to GVAX Prostate, BioSante has several other cancer vaccines which are in Phase II clinical development including vaccines for leukemia, breast cancer and pancreatic cancer. Also, BioSante has applied for and received four FDA Orphan Drug designations for cancer vaccines to treat acute myeloid leukemia, chronic myeloid leukemia, pancreatic cancer and melanoma.
About the Prostate Cancer Foundation (PCF)
The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for accelerating the world's most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $450 million and provided funding to more than 1,500 researchers at nearly 200 institutions worldwide. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a 20-fold increase in government funding for prostate cancer. More information about the PCF can be found at www.pcf.org.
About the OneInSix Foundation
The OneInSix Foundation is so-named because one in six American men will be diagnosed with prostate cancer. This charitable organization was founded by the late Mr. Bruce Hunsicker, an attorney from Akron, Ohio who dedicated his time and effort to raising funds for prostate cancer research and awareness.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com

Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).

Wind Stocks Trading News Alert; (NasdaqGS: BWEN), (OTCBB: CWET), (CYW.F), (NYSE: MY), (Copenhagen: VWS.CO) - Bullish Outlook Long Term for Renewables

Point Roberts, WA - June 3, 2011 - Investorideas.com, a leader in cleantech stock research, issues a wind stocks trading alert for Broadwind Energy, Inc. (NasdaqGS: BWEN) ,Clean Wind Energy Tower, Inc. (OTCBB: CWET), City Windmills, Ltd. (CYW.F) and Vestas Wind Systems (Copenhagen: VWS.CO). The outlook for renewable energy and wind energy is bullish for the long term according a report by the IPCC.

According to a report in May, 'Potential of Renewable Energy' by the Intergovernmental Panel on Climate Change (IPCC), renewable energy, "Close to 80 percent of the world‘s energy supply could be met by renewables by mid-century if backed by the right enabling public policies.”
The report also noted, "Despite global financial challenges, renewable energy capacity grew in 2009 - wind by over 30 percent; hydropower by three percent; grid-connected photovoltaics by over 50 percent; geothermal by 4 percent and solar water/heating by over 20 percent.”
More: http://srren.ipcc-wg3.de/press/content/potential-of-renewable-energy-outlined-report-by-the-intergovernmental-panel-on-climate-change
Wind Stocks Snapshot

• Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading at $1.60, down 0.06 (3.61%) 1:28PM EDT
• Catch the Wind Ltd. (TSX-V: CTW) trading at $0.46
• China Ming Yang Wind Power Group (NYSE: MY ) trading at$6.17, down 0.72 (10.45%) 1:34PM EDT
• City Windmills, Ltd. (CYW.F) trading at $1.55
• Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.28
• Vestas Wind Systems (Copenhagen: VWS.CO ) trading at $ 153.30, down 2.90 (1.86%)

Market Snapshot

• Dow 12,188.72 -59.83 -0.49%
• Nasdaq 2,751.92 -21.39 -0.77%
• S&P 500 1,306.76 -6.18 -0.47%
• 10 Yr Bond(%) 3.0060% -0.0240
• Oil 100.10 -0.30 -0.30%
• Gold 1,542.20 +10.20 +0.67%

Recent Wind News:
Clean Wind Energy Tower, Inc. (OTCBB: CWET) Letter to Shareholders
ANNAPOLIS , MD - May 31, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc. (OTCBB: CWET) (the "Company") announced that the Company had communicated to their shareholders of record in a letter that stated: Full news: http://www.investorideas.com/CO/CWE/news/2011/05311.asp
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET) was established to commercialize a number of proven and validated technologies and construction systems into a single large downdraft tower structure that produces abundant inexpensive electricity.
www.cleanwindenergytower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Visit the profile for City Windmills, Ltd. (CYW.F)
http://www.investorideas.com/CO/CYW
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. City Windmills, Ltd. (CYW.F) is a paid advertising client on Investorideas.com and related blogs (thirty five hundred, five thousand shares per month)
Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dawn@investorideas.com or cvanzant@investorideas.com

Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks (OTCBB: AEMD), (NYSE: MRK) and (VRTX)

Point Roberts, WA - June 3, 2011 - Investorideas.com, a leader in sector stock issues a trading alert for biotech/pharma stocks Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc (VRTX). Merck & Company, Inc.(NYSE: MRK ) following recent news and developments for the treatment of Hepatitis C Virus (HCV). The month of May broke headlines for both Merck (NYSE: MRK) and Vertex Pharmaceuticals Inc (VRTX).

Merck (NYSE: MRK) announced May 13 th that the U.S. Food and Drug Administration (FDA) had approved VICTRELIS™ (boceprevir), for the treatment of chronic hepatitis C (CHC). Following on its heels, Vertex Pharmaceuticals Inc (VRTX) announced May 23 rd that theFDA approved INCIVEK™ (telaprevir).
Aethlon Medical, Inc. (OTCBB: AEMD) reported President Rodney S. Kenley will discuss the role of the Aethlon Hemopurifier® in the treatment of hepatitis C virus (HCV) in an upcoming presentation at the 20th International Vicenza Course of Hemodialysis and CKD (chronic kidney disease) on Wednesday, June 8, 2011 in Vicenza, Italy.
Trading Snapshot (As of close of trading June 2nd)

• Aethlon Medical, Inc. (OTCBB: AEMD) closed at $ 0.1044, up 0.0044 (4.40%)
• Merck & Company, Inc. (NYSE: MRK) closed at $ 36.15, down 0.10 (0.28%)
• Vertex Pharmaceuticals Inc (VRTX) closed at $ 54.50, up $1.48 (2.79%)

Hepatitis C Virus (HCV) News:
Aethlon Medical (OTCBB: AEMD) President Rodney S. Kenley to Present at the 20th International Vicenza Course on Hemodialysis and CKD
SAN DIEGO - June 2, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD) today announced that Company President Rodney S. Kenley will discuss the role of the Aethlon Hemopurifier® in the treatment of hepatitis C virus (HCV) in an upcoming presentation at the 20th International Vicenza Course of Hemodialysis and CKD (chronic kidney disease) on Wednesday, June 8, 2011 in Vicenza, Italy. The Aethlon Hemopurifier® is a first-in-class therapeutic filtration device that selectively removes infectious viruses and immunosuppressive toxins from the entire circulatory system through the use of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
Mr. Kenley's presentation, "The Treatment of HCV with Affinity Plasmapheresis on Dialysis Machines," will focus on treating HCV in existing dialysis clinics with no change in infrastructure or capital investments. The Hemopurifier® can be used to treat HCV in dialysis patients, in whom the prevalence of HCV is over 100 times higher than in the general population, as well as to treat non-dialysis patients.
Full News: http://www.investorideas.com/CO/AEMD/news/2011/06021.asp
Vertex Pharmaceuticals Inc (VRTX ) News: FDA Approves INCIVEK™ (telaprevir) for People with Hepatitis C

• 79% of people treated for the first time achieved a SVR (viral cure) with INCIVEK combination treatment-
• Vertex launches a comprehensive financial assistance and patient support program-

CAMBRIDGE, Mass.-May 23, 2011, Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX ) today announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver). INCIVEK (in-SEE-veck) is approved for people who are new to treatment, and for people who were treated previously but who did not achieve a viral cure (relapsers, partial responders and null responders). INCIVEK is given for 12 weeks in combination with pegylated-interferon and ribavirin, two other medicines approved to treat hepatitis C. After the first 12 weeks, all patients stop receiving INCIVEK and continue treatment with pegylated-interferon and ribavirin alone for an additional 12 weeks or 36 weeks of treatment. With INCIVEK combination treatment, more than 60 percent of people treated for the first time, as well as those who relapsed after previous therapy, are expected to complete all treatment in 24 weeks - half the time needed if they were to take pegylated-interferon and ribavirin alone. All other patients will receive a total of 48 weeks of treatment. INCIVEK will arrive in pharmacies this week.
Full News: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=580154
FDA Approves Merck's VICTRELIS™ (boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor
WHITEHOUSE STATION, N.J., May 13, 2011 - Merck (NYSE: MRK ) (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has approved VICTRELIS™ (boceprevir), the company's innovative new medicine for the treatment of chronic hepatitis C (CHC). VICTRELIS is approved for the treatment of CHC genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years of age and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.
Full news:http://www.merck.com/newsroom/news-release-archive/prescription-medicine-news/2011_0513.html?WT.svl=content&WT.pi=content+Views
Company Snapshot
About Aethlon Medical (OTCBB: AEMD)
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3. Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4. Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Contact:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011       
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011

Water Stocks News; Wescorp Energy (OTCBB:WSCE) Announces H2Omaxx Compatibility with Reverse Osmosis to Broaden Market Horizons

CALGARY - June 2, 2011 (Investorideas.com Water Stocks Newswire) - Wescorp Energy Inc. (Wescorp) (OTCBB:WSCE.ob), a clean water technology company focused on implementing cost-effective solutions into several markets, including the oil and gas and marine industries, announced today that the second generation 10,000 barrel per day (bpd) H2Omaxx when paired with a reverse osmosis (RO) unit achieves high standards of water decontamination required for surface water discharge.

"Based on the demonstration, the capability of the H2Omaxx to efficiently remove the hydrocarbons and suspended solids from water contaminated with a wide range of contaminates is a significant benefit for clients that need the highest standards of water cleaning and water quality" stated Vern Graham, Vice-President of Formation Fluid Technologies Inc, owner of the advanced membrane technology process used in the test. "Membrane technology has powerful water cleaning capability for a wide range of contaminants, but its capability can be impaired, and often made uneconomical as a solution for clients, by the presence of hydrocarbons and/or suspended solids in the water needing treatment. By working with the H2Omaxx technology, we are able to deliver to the customer a mobile, compact, on-site treatment system that provides the customer with the option to avoid trucking large volumes of contaminated water to expensive off-site treatment facilities".The water from an industrial site contains a wide range of contaminants, including hydrocarbons, dissolved metals and suspended solids. The objective was to enable the client to be able to treat the contaminated water on-site, and to meet stringent surface water quality standards. Achieving these standards means that the water can be safely discharged into rivers, lakes and harbours, rather than being hauled away for remote treatment as hazardous fluids. The Canadian Hazardous Waste Removal (HWR) and Contaminated Site Regulation (CSR) standards and the Province of British Columbia Contaminated Site Regulations were applied in defining the trial results.

Wescorp wanted to determine if the H2Omaxx could be combined with other technologies to provide a clean water technology solution for a customer base beyond the oil and gas industry. The H2Omaxx technology has proven to clean contaminated oil field produced water that includes hydrocarbons, paraffin and waxes. Suspended solids, including sand, metal fragments and other particulate matter, can also be removed. The water remediation challenges faced by the oil and gas industry are not unique and exist in other industries.

"We have now demonstrated that there is another treatment option for complex contaminated water challenges faced by industrial sites. Industries that have a need to return their used water to the environment can now look to Wescorp's H2Omaxx technology coupled with RO technology for a scalable, mobile solution that will facilitate on-site water treatment," said Robert G. Power, Executive Chairman of Wescorp's Board. "With increasing regulatory and economic pressure to reclaim industrial waste water, Wescorp has been approached by industrial and environmental remediation companies interested in utilizing the H2Omaxx technology. Wescorp will explore these opportunities further in the coming months."

Third party sampling of the water before and after treatment, and reporting of the analytical results, was conducted by a national environmental consulting firm hired by the industrial customer directly.

About Wescorp Energy Inc.

Wescorp (www.wescorpenergy.com) is a clean water technology company focused on implementing its superior, low-cost, water purification solutions for the oil and gas production industry and for marine remediation projects across North America. Wescorp's innovative clean technology is designed to meet increasing government regulations needs of our industry and society in general.

About Formation Fluid Technologies Inc.

Formation Fluid Technologies Inc. (formationfluid.com) is a specialized water engineering and services company focused primarily on the oil and gas industry. The company provides onsite water purification services for energy producers to recycle and reuse the water produced during extraction. Formation Fluid's mission is to create, develop and cost-effectively solve a significant industry and environmental challenge.

About the H2Omaxx Technology

H2Omaxx utilizes proprietary next generation aeration technology to clean and separate oil and solids from water. It has been proven to be safe, effective, economical and an environmentally-friendly process. Independent test results have shown the H20maxx technology will reduce the oil content in oil well produced water to less than 10 parts per million without the use of chemicals, filters or heat.

Safe Harbour Statement

Any statements contained herein that are not historical facts may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company, are based on certain assumptions, and involve known and unknown risks and uncertainties. Many factors could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Information on the potential factors that could affect the Company's actual results of operations as well as other risks to the Company or its business may be further discussed in periodic reports and registration statements to be filed by the Company from time to time with the U.S. Securities and Exchange Commission.

Disclosure/disclaimer - All investment involves risk and possible loss of entire investment Wescorp (OTCBB: WSCE is former paid advertising showcase stock by a third party; 2500 per month plus 100, 00 stock options at .25). Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites.

Compensation Disclosure and disclaimers:
www.InvestorIdeas.com/About/Disclaimer.asp,
http://www.investorideas.com/About/News/Clientspecifics.asp

Cloud Computing Stock News; Leading IBM Business Partner Launches Next Generation Offering for Converting Lotus Notes Applications

NEW YORK - June 2, 2011 (Investorideas.com cloud computing stocks newswire) – GBS Enterprises (OTCBB:GBSX), announced that its subsidiary, GROUP Business Software AG, has unveiled a combination of expert services and accelerator tools, called Transformer 2.0, that allows enterprises to transfer large portfolios of Lotus Notes applications to the Web. The launch event was held was held in conjunction with IBM (NYSE:IBM) at the Massachusetts Institute of Technology (MIT) Museum in Cambridge MA on the evening of May 25, 2011. The location was significant because MIT is world renowned for fostering innovation and advancement in technology and Cambridge was also the birthplace of Lotus.

"Helping our customers move to a future with rich capabilities in the cloud is extremely important to our Notes and Domino community," stated Kristen Lauria, VP of Marketing, IBM Collaboration Solutions. "It is a game changer. GBS has provided our customers with a path to transform their Lotus business applicationsto the next generation of web and mobile-capable collaborative applications."Speaking at the event were Joerg Ott, CEO and other executives of GBS Enterprises along with Alistair Rennie, GM, IBM Collaboration Solutions, Kristen Lauria, VP of Marketing, IBM Collaboration Solutions, and Kevin Cavanaugh, VP Business & Technical Strategy, IBM Collaboration Solutions. The event also featured Ryan Chin, Research Specialist at MIT who talked about some of the newest innovations being developed.

For the first time, organizations have a set of analytical and executable processes that transform their existing Lotus Notes rich client applications on to the Web, where they can now be run in the cloud, on mobile devices and be more easily integrate with social media platforms. Transformer provides the continuity of the past with all the benefits that are now available in the latest release of IBM Domino.

This comes at a time when organizations are rapidly embracing new ways to develop and deliver applications to their users. By 2014, 40% of all new business applications will be delivered via subscription or self-service via cloud technology. With over 10 million active Lotus Notes applications worldwide, it is no surprise there is increasing pressure on organizations to web-enable these applications. The challenge is doing so without having to invest in time and resource intensive re-development projects, risky data migration and costly retraining of staff.

GBS points to the very high demand for these conversions as proof companies want to migrate and have not been able to figure out how. "Every day we see companies wanting to move their applications to take advantage of the web, but they have been unable to justify the high financial cost," says Joerg Ott, CEO of GBS. "Transformer provides a turnkey solution combining platform expertise with technology, allowing clients to preserve their existing investments in intellectual capital."

For nearly 20 years, GBS has been singularly focused on delivering compelling business solutions and innovation to the Lotus market. Building on this expertise GBS has developed a comprehensive set of tools and services to plan and execute an orderly and fast migration. "Trying to migrate these applications to a totally different technology like Sharepoint or Google Apps, is disruptive and requires huge amounts of money and time," says Scott Hooks, GM of GBS Experts division. "To be effective, you must have the expertise to know what to do and the technology to do it."

Recent enhancements provided in Transformer 2.0 are:

• Transformer Investigator -- collects statistics on which applications are being used, how often and by whom so that an organization can target which applications have the highest impact to transform.
• Transformer Extension Library - allows a variety of enhancements to be applied to all aspects of transformed applications without writing any additional code.
• GBS WebSpace -- is a web enabled version of the familiar Notes client Workspace.
• Support of Object Oriented Programming.
• Ability to maintain application business logic in LotusScript.

About GBS Enterprises, Inc.

GBS Enterprises (OTCBB:GBSX), is the parent company of Group Business Software which provides product and services for the IBM Lotus market. The company boasts more than 4,000 customers worldwide with more than 4 million users of their products and services. GBS has offices in New York, Boston, Atlanta, Toronto, London, Manchester, Copenhagen, and throughout Germany. Its European headquarters is in Frankfurt, Germany and North American headquarters is located in New York City. For more information please visitwww.gbs.com.

Contact:

GROUP Business Software: 
Marketing and Communications Contact: Michael Baum 
Corporate Communications, michael.baum@us.gbs.com

GBS Enterprises: 
Investor Relations Contact: 
Gary MacDonald, EVP and Chief Business Development Officer 
gmacdonald@gbsx.us Tel: 917-477-9509

Visit the GBSX company profile on Investorideas.com
Request news and info on GBSX

Disclosure: GBS Enterprises, Inc. (OTCBB:GBSX) is a paid showcase tech stock, cloud computing stock on Investorideas.com (April 2011 - 1500 per month by third party)

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Nanotechnology Stocks; mPhase (OTC.BB:XDSL) Completes Working Prototype of New Automative Product Using Advanced Battery Technology

LITTLE FALLS, NJ - June 2, 2011 (Investorideas.com Newswire) - mPhase Technologies, Inc. (OTC.BB: XDSL) today said that it has completed its first working prototype of a new automotive product.

Working with a renowned European automobile manufacturer has resulted in a high quality, functional and distinguished product design. The new product, featuring advanced battery technology, is expected to have broad appeal to both the OEM and aftermarket automotive and marine industry.
"The company has decided to keep the new product under wraps in order to protect our intellectual property from being reverse engineered and establish a first to market advantage," said Ronald A. Durando CEO of mPhase.
About mPhase Technologies, Inc.
mPhase Technologies is introducing a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab on a chip analytic systems, self cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery.
In addition to the Smart Surface technology, mPhase recently introduced its first product, the mPower Emergency Illuminator, an award-winning product designed by Porsche Design Studio. http://www.mpowertech.com
Forward Looking Statements
As a cautionary note to investors, certain matters discussed in this press release may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company s products in the market; the Company s success in technology and product development; the Company s ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company s SEC filings, including the financial statements and related information contained in the Company s SEC Filing. mPhase assumes no obligation to update the information in this release.
Contact:
mPhase Technologies, Inc. 973 256 3737

Visit the XDSL showcase profile at Investorideas.com
Request News and Info on XDSL
Disclosure, Disclaimer/ XDSL is a paid advertising client on Investorideas.com and our technology portals.

Stem Cell Stock News; Vitro (OTCQB: VODG) Appoints Accomplished Finance Executive to Its Advisory Board

GOLDEN, Colo. � June 2, 2011 (Investorideas.com Newswire) - Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, is pleased to announce the appointment of Duane C. Knight, Jr., CPA, to its Scientific Advisory Board. While officially a Scientific Advisory Board, this group of individuals provides their scientific and business acumen to assist the Company in the achievement of its overall goals. Mr. Knight has more than twenty-five years' experience in consulting, accounting and corporate finance. He is presently Operational Chief Financial Officer of Neuromonics, Inc., a medical device company that manufactures and distributes an FDA-approved and patented device to treat tinnitus, ringing in the ears, to global markets. He has an accomplished record in business finance including partnership of a Denver, CO-based investment bank, CFO of another medical device firm and owner of a public accounting and consulting firm. Mr. Knight was brought in to assist in the ongoing business development activities of the Company, especially as related to turn-around to profitability and the achievement of sustained earnings growth and other relevant financial activities. Mr. Knight�s addition to Vitro�s management team complements and extends the technical and business expertise of its team that includes, in addition to Mr. Knight, two directors & officers who have extensive scientific and business experience together with two additional SAB members who provide scientific and business input to the Company.

From 2009 to the present, Mr. Knight is the Operational Chief Financial Officer of Neuromonics, Inc., a privately held Australian firm, that is one of the only firms to offer an FDA-approved treatment of tinnitus, an often debilitating condition with continual ringing in the ears without auditory input. He oversees operations, finance (including a $2-million fund raise), accounting, auditing interface, HR and administration, corporate governance and IT. From 2007 to 2009, he was a partner of Trinity Capital Services, LLC, a Denver, CO-based investment bank, where he headed up the life science practice, while directing FINRA compliance, numerous private placements into client firms and sell side M&A engagements. From 2002 to 2007, he was Chief Financial Officer and VP of Finance of Denver Biomedical, Inc., a medical device firm that developed a novel catheter for the treatment of excess fluid buildup in typically terminally ill cancer patients. During his tenure, his responsibilities included business development that yielded 25% CAGR and EBITA CAGR of 34%. He was also responsible for gaining coverage by private insurance (Aetna) and Medicare reimbursement. He led several significant transactions including exit of a venture partner, recapitalization with a private equity firm, debt refinancing and ultimately, sale of the company to Cardinal Health, Inc. He was retained by Cardinal Health, Inc. to complete post-acquisition finance and integration/transition activities. Prior to 2002, Mr. Knight established his own public accounting and consulting firm and performed finance operations for various public and private firms, and was a senior audit manager for Hein & Associates, LLP.
Mr. Knight said, "I am pleased to join Vitro�s SAB at this point of its development and plan to use my experience and my connections within the biomedical and financial industry to assist Vitro in attaining sustained profitability by leveraging the strong competitive advantages of its present line of stem cell-based products to capture of significant global market share. There is a dynamic growth opportunity within the stem cell sector due to the demonstrated abilities of stem cell technology to radically alter regenerative medicine through advanced treatments of numerous untreatable and under treated diseases, injuries and age-related degenerative conditions."
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG) (http://www.vitrobiopharma.com), owns U.S. patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro also owns a pending international patent for generation of pluripotent stem cells. Vitro's mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, optimized media for stem cell self-renewal and lineage-specific differentiation. Vitro recently formed a strategic alliance with HemoGenix�, Inc. (http://www.hemogenix.com/) to jointly manufacture and distribute Lumenesc™ and LumiSTEM™ quantitative assays for determination of stem cell quality, potency and response to toxic agents.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.
1. Market research data provided by BCC Research.
Contact:
Vitro Diagnostics, Inc.
Dr. James Musick, 303-999-2130
Chief Executive Officer
jim@vitrodiag.com

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB:VODG) is a profiled stem cell stock at Investorideas.com
Visit the VODG company profile on Investorideas.com

Request News and Info on VODG

Disclosure, Disclaimer/ Disclosure -Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB:VODG) showcase stem cell stock, one month, $one thousand, April - May 2011

Mississippian Formation Oil and Gas Stock Trading Snapshot; (NYSE: CHK), (NYSE: DVN), (OTCBB: OEDV), (NYSE: RRC), (NYSE: SD)

Point Roberts, WA. June 2, 2011 (Investorideas.com Energy Newswire) - www.InvestorIdeas.com, a leader in sector research including oil and gas stocks, issues a trading snapshot on several of the Mississippian Formation oil and gas stocks recently in the news.

Mississippian Formation Sector Trading Snapshot

• Chesapeake Energy Corporation (NYSE: CHK ) trading at $30.71, up 0.32 (1.05%) 10:55AM EDT
• Devon Energy Corporation (NYSE: DVN ) trading at $83.25, up 0.48 (0.58%) 10:54AM EDT
• Osage Exploration and Development, Inc. (OTCBB: OEDV) trading at $0.28
• Range Resources Corporation (NYSE: RRC ) trading at $53.79, up 0.36 (0.67%) 10:55AM EDT
• SANDRIDGE ENERGY INC (NYSE: SD ) trading at $11.16, up 0.04 (0.36%) 10:55AM EDT

Market Snapshot

• Dow 12,281.89 -8.25 -0.07%
• NASDAQ 2,781.56 +12.37 +0.45%
• S&P 500 1,315.66 +1.11 +0.08%
• 10 Yr Bond (%) 2.9950% +0.0290
• Oil 100.48 +0.19 +0.19%
• Gold 1,534.80 -7.60 -0.49%

In a recent Q&A with Investorideas.com, Kim Bradford, President and CEO of Osage Exploration and Development, Inc. discusses the players in the Mississippian Formation;
"There are more than a dozen that I could name offhand. What is interesting is that in almost every case, it is Oklahoma based companies that are in this play. Ranging from very long term privately owned Oklahoma drillers such as Nadel & Gussman and Ceja, which date back to the 20's and 30's to Eagle Energy which was founded in 2009, all are finding success in the Horizontal Miss. The publicly traded companies such as Chesapeake Energy, Devon Energy, SandRidge Energy, and Range Resources with a combined market cap of almost $70 billion lend a tremendous amount of credence to the play by their very presence. It is fair to say that at least in SandRidge Energy's case, its commitment to the Oklahoma Mississippian play has totally transformed the company from a lackluster natural gas focused producer to one of the most dynamic mid sized oil companies in the market today, with a stock price performance to match that transformation going from $4 less than a year ago to roughly $12 today. If you go to their website, and you should, it is obvious that they largely credit the Horizontal Miss for that transformation.
The attribute that all the Horizontal Miss players seem to have, beyond the fact that they are almost unanimously Oklahoma companies with detailed local knowledge, is that they have been largely driven by people of conviction, ranging from most notably Tom Ward at SandRidge Energy to Loren Schmidt at Calyx, Charles Wickstrom and Shane Matson at Spyglass Energy, as well as Osage's own Greg Franklin, and many others. While the Mississippian formation has been known for decades, it took the ability to re-evaluate without prejudice, and move forward with conviction that the Mississippian could be an ideal candidate for horizontal exploitation.
Because the Mississippian is present in so many counties in Oklahoma, each of the companies involved are making unique contributions to the knowledge base. As an example, Pablo Energy and Eagle Energy of Oklahoma are in completely different areas of Oklahoma, use completely different drilling and completion techniques, but are helping us all to advance our knowledge and build efficiencies. Oklahoma is a fantastic place todrill for oil and these are fantastic people and companies to be working along beside.”
More aboutOsage (OTCBB: OEDV)
Osage Exploration and Development, Inc. ( OTCBB: OEDV)
Based in San Diego, California with production offices in Oklahoma City, Oklahoma, and executive offices in Bogotá, Colombia, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the US and Colombia. www.osageexploration.com
Follow (OTCBB: OEDV) on Twitter.com
http://twitter.com/#!/OsageOEDV
Visit the Osage (OTCBB: OEDV) company showcase profile at Investorideas.com
http://www.investorideas.com/CO/OEDV/
Company News:
Osage (OTCBB: OEDV) Joint Ventures Its 10,000 Acre Horizontal Mississippian Nemaha Ridge Project
Full News: http://www.investorideas.com/CO/OEDV/news/2011/05261.asp
Company Q&A: Q&A Interview with Kim Bradford, President and CEO of Osage (OTCBB: OEDV), Following News of Joint Venture with Slawson Exploration Company, Inc. and U.S. Energy Development Corporation
Full interview: http://www.investorideas.com/CO/OEDV/news/2011/05312.asp
Request news and trading alerts on OEDV
http://www.investorideas.com/Resources/Newsletter.asp
Research more oil and gas stocks with the oil and gas stock directory at Investorideas.com - lists over 600 stocks including Bakken stocks
http://www.investorideas.com/OGSN/Stock_List.asp
Disclaimer: Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Disclosure: OEDV is a paid advertising oil and gas company on Investorideas.com - Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
800-665-0411 - cvanzant@investorideas.com or dawn@investorideas.com
Source - Investorideas.com

Osage Exploration and Development, Inc. (OEDV.OB) is a showcase oil and gas stock on Investorideas.com
Visit the company showcase profile at Investorideas.com
Request news and stock alerts for Osage Exploration and Development, Inc. (OEDV.OB)
Disclosure: (6 months starting May 24, 2011 thirty five hundred per month, 100,000 144 shares)